TY - JOUR
T1 - Positron emission tomography and radioimmunotargeting - General aspects
AU - Lundqvist, Hans
AU - Lubberink, Mark
AU - Tolmachev, Vladimir
AU - Lövqvist, Anna
AU - Sundin, Anders
AU - Beshara, Soheir
AU - Bruskin, Alexander
AU - Carlsson, Jörgen
AU - Westlin, Jan Erik
N1 - Funding Information:
We thank Professor Bengt Långström, head of the Uppsala PET Centre and his colleagues for valuable discussions. Financial support was given by the Swedish Cancer Society and by the Swedish Medical Research Council. We would also like to thank the The Svedberg Laboratory for technical help.
Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1999
Y1 - 1999
N2 - To optimize radioimmunotherapy, in vivo information on individual patients, such as radionuclide uptake, kinetics, metabolic patterns and optimal administration methods, is important. An overriding problem is to determine accurately the absorbed dose in the target organ as well as critical organs. Positron Emission Tomography (PET) is a superior technique to quantify regional kinetics in vivo with a spatial resolution better than 1 cm3 and a temporal resolution better than 10 s. However, target molecules often have distribution times of several hours to days. Conventional PET nuclides are not applicable and alternative positron-emitting nuclides with matching half-lives and with suitable labelling properties are thus necessary. Over many years we have systematically developed convenient production methods and labelling techniques of suitable positron nuclides, such as 110In(T 1/2 = 1.15 h), 86Y(T 1/2 = 14 h), 76Br(T 1/2 = 16 h) and 124I(T 1/2 = 4 days). 'Dose planning' can be done, for example, with 86Y- or 124I-labelled ligands before therapy, and 90Y- and 131I-labelled analogues and double-labelling, e.g. with a 86Y/90Y-labelled ligand, can be used to determine the true radioactivity integral from a pure beta- emitting nuclide. The usefulness of these techniques was demonstrated in animal and patient studies by halogen-labelled MAbs and EGF-dextran conjugates and peptides chelated with metal ions.
AB - To optimize radioimmunotherapy, in vivo information on individual patients, such as radionuclide uptake, kinetics, metabolic patterns and optimal administration methods, is important. An overriding problem is to determine accurately the absorbed dose in the target organ as well as critical organs. Positron Emission Tomography (PET) is a superior technique to quantify regional kinetics in vivo with a spatial resolution better than 1 cm3 and a temporal resolution better than 10 s. However, target molecules often have distribution times of several hours to days. Conventional PET nuclides are not applicable and alternative positron-emitting nuclides with matching half-lives and with suitable labelling properties are thus necessary. Over many years we have systematically developed convenient production methods and labelling techniques of suitable positron nuclides, such as 110In(T 1/2 = 1.15 h), 86Y(T 1/2 = 14 h), 76Br(T 1/2 = 16 h) and 124I(T 1/2 = 4 days). 'Dose planning' can be done, for example, with 86Y- or 124I-labelled ligands before therapy, and 90Y- and 131I-labelled analogues and double-labelling, e.g. with a 86Y/90Y-labelled ligand, can be used to determine the true radioactivity integral from a pure beta- emitting nuclide. The usefulness of these techniques was demonstrated in animal and patient studies by halogen-labelled MAbs and EGF-dextran conjugates and peptides chelated with metal ions.
UR - http://www.scopus.com/inward/record.url?scp=0033040568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033040568&partnerID=8YFLogxK
U2 - 10.1080/028418699431410
DO - 10.1080/028418699431410
M3 - Article
C2 - 10380825
AN - SCOPUS:0033040568
VL - 38
SP - 335
EP - 341
JO - Acta Oncologica
JF - Acta Oncologica
SN - 0284-186X
IS - 3
ER -